Harvard Bioscience holder reports 5.2% stake
HARVARD BIOSCIENCE INC (HBIO) received an amended Schedule 13G/A (Amendment No. 8) reporting that Adam M. Hutt, through Leviticus Partners, beneficially owns 235,000 shares of its common stock, representing 5.2% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HARVARD BIOSCIENCE INC (HBIO) received an amended Schedule 13G/A (Amendment No. 8) reporting that Adam M. Hutt, through Leviticus Partners, beneficially owns 235,000 shares of its common stock, representing 5.2% of the class.
Hutt reports sole voting and sole dispositive power over all 235,000 shares, with no shared voting or dispositive power.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of HARVARD BIOSCIENCE INC (HBIO) does Adam M. Hutt report owning in this Schedule 13G/A?
When was this Amendment No. 8 to the Schedule 13G/A for HBIO signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.